Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it has submitted a Biologics ...
The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), ...
Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
AbbVie said on Monday it would partner with Chinese drug developer RemeGen for an experimental treatment targeting solid ...
Phanes Therapeutics reports positive phase 2 results of spevatamig in combo with chemotherapy in frontline treatment of metastatic PDAC: San Diego Monday, January 12, 2026, 18:00 ...
Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma industry by market cap. | Two investigational cardiometabolic drugs from Eli ...
Driven by a paradigm shift to curative early-stage interventions and surging ADC demand, the market offers massive upside.
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a biotech company focused on advancing cancer treatments, has engaged IBN, a multifaceted financial news and publishing company serving private and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback